BioFirst’s "Artificial Vitreous" received recognition from European ophthalmic pharmaceuticals with MOU signed.

 

The Vitreous Substitute that developed by the medical device pharmaceuticals, BioFirst, received recognition from European ophthalmic pharmaceuticals and signed a licensing MOU. BioFirst indicated that with the developing of smartphones and trend of world aging, renal diseases has been more common than ever. Needs for Vitreous Substitute has increased nowadays. Therefore, global biotechnology factory are willing to try and negotiate for a chance of corporation. From now on, there had corporations that form U.S., China and Italia connected with BioFirst. BioFirst mentioned that the therapy of renal diseases is to inject gas or silicon oil as Vitreous Substitute. The weakness is that patients have to lie prone on the bed for few days to weeks; or take out silicon oil by second surgery. BioFirst developed Vitreous Substitute, which made from hyaluronic acid and with high safety. It can soon transfer into gel and maintain for several weeks. It will degrade and discharge gradually without surgery and lie on bed. It has a great market because it solves difficulties of existing product. BioFirst further indicated that their aim is the world market and shine people’s eye. The global market size of artificial vitreous is estimated US$2 Billion annually, Europe will be one of the major market, strategically partner with EEC countries with authorization agreement will establish a solid foundation for entering European market successfully.